OBI-998 / OBI Pharma - LARVOL DELTA

[VIRTUAL] Preclinical characterization of a novel SSEA-4-targeting antibody drug conjugate, OBI-998 (AACR 2021) - "More importantly, OBI-998 at a dose of 10 mg/kg showed complete tumor regression in an EGFR-triple mutation non–small cell lung cancer xenograft model, which is resistant to the current last-line tyrosine kinase inhibitor, osimertinib. Furthermore, OBI-998 showed a high level of deposition and a persistent presence of MMAE in tumors and significant anti-tumor efficacy in a variety of animal models. Taken together, these results support the further development of OBI-998 as a therapeutic agent for SSEA-4-targeting cancer therapy."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4 (PRNewswire) - "OBI Pharma, Inc...announced the data highlighting the characteristics and antitumor efficacy of OBI-3424 and animal studies of OBI-998, as well as the T-cell inhibitory roles of Globo-H and SSEA-4 in the tumor microenvironment, will be presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting from April 10–15, 2021."

Preclinical • Oncology